Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplet Therapy vs Standard of Care in Platinum-Resistant Ovarian Cancer
NCT04739800Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab, olaparib, cediranib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Started Jun 2021; status: active, not recruiting.
02
Drugs
durvalumabolaparibcediranib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT04739800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739800.